Divalproex Sodium Tablet, Film Coated, Extended Release
Product Images NDC 0378-0472

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 0378-0472). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Divalproex Sodium Extended-release Tablets 250 mg Bottle Label (Image 01)

Divalproex Sodium Extended-release Tablets 250 mg Bottle Label (Image 01)
Label for Divalproex Sodium Extended-Release Tablets, USP 250 mg, film-coated extended-release oral tablets. The label indicates once-daily dosing and contains 100 tablets. Manufactured by Mylan Pharmaceuticals Inc., Morgantown, WV, and made in Puerto Rico. Includes instructions for storage and handling, emphasizing dispensing in a light-resistant container with child-resistant closure.*
FDA Label Image

Divalproex Sodium Extended-release Tablets 500 mg Bottle Label (Image 02)

Divalproex Sodium Extended-release Tablets 500 mg Bottle Label (Image 02)
Label for Divalproex Sodium Extended-Release Tablets, USP 500 mg by Mylan Pharmaceuticals Inc. The label indicates film-coated, extended-release oral tablets with 100 tablets per container. Includes storage instructions, a barcode, NDC 0378-0473-01, and pharmacist dispensing guidance. Manufactured by Mylan Pharmaceuticals in Puerto Rico.*
FDA Label Image

Divalproex Sodium Structural Formula (Image 03)

Divalproex Sodium Structural Formula (Image 03)
Chemical structure of divalproex sodium, depicting its molecular components and arrangement as seen in the structural formula diagram.*
FDA Label Image

Figure 1: Proportion Of Patients (x Axis) Whose Percentage Reduction From Baseline In Complex Partial Seizure Rates Was At Least As Great As That Indicated On The Y Axis In The Adjunctive Therapy Study (Image 04)

Figure 1: Proportion Of Patients (x Axis) Whose Percentage Reduction From Baseline In Complex Partial Seizure Rates Was At Least As Great As That Indicated On The Y Axis In The Adjunctive Therapy Study (Image 04)
Chart showing percentage reduction in CPS rate versus percentage of patients for Divalproex Sodium Delayed-Release and placebo. The solid line represents Divalproex Sodium Delayed-Release with greater improvement in CPS rate compared to the dashed line for placebo, indicating changes from worsening to improvement across patient percentages.*
FDA Label Image

Figure 2: Proportion Of Patients (x Axis) Whose Percentage Reduction From Baseline In Complex Partial Seizure Rates Was At Least As Great As That Indicated On The Y Axis In The Monotherapy Study (Image 05)

Figure 2: Proportion Of Patients (x Axis) Whose Percentage Reduction From Baseline In Complex Partial Seizure Rates Was At Least As Great As That Indicated On The Y Axis In The Monotherapy Study (Image 05)
A cumulative distribution plot showing percent reduction in CPS rate versus percent of patients for high dose and low dose Divalproex Sodium Delayed Release. The y-axis represents percent change in CPS rate, ranging from worsening to improvement, with a clear zero change line. The x-axis shows percent of patients from 0 to 100.*
FDA Label Image

Figure 3. Mean Reduction In 4-week Migraine Headache Rates (Image 06)

Figure 3. Mean Reduction In 4-week Migraine Headache Rates (Image 06)
A bar chart comparing placebo and Divalproex Sodium Extended-Release Tablets. The y-axis shows a numeric scale up to 1.2. The placebo bar is lower (0.6) than the Divalproex Sodium bar (1.2), indicating a measured comparison between the two groups with a noted significance value (p=0.006).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.